András Fogarasi

András Fogarasi

Auto-generated profile, based on publicly available information

András Fogarasi

Epilepsy Center, Bethesda Children's Hospital, Budapest, Hungary

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2006 in Epilepsia
Verified
Journal Article
Closed access
PDF file
AFAndrás Fogarasi
András Fogarasi
JJJózsef Janszky
József Janszky
ITIngrid Tuxhorn
Ingrid Tuxhorn

7 January 2020 in Epilepsia
Verified
Journal Article
Open access
PDF file
AFAndras Fogarasi
Andras Fogarasi
RFRobert Flamini
Robert Flamini
MMMathieu Milh
Mathieu Milh
SPSteven Phillips
Steven Phillips
SYShinsaku Yoshitomi
Shinsaku Yoshitomi
LNLeock Y. Ngo
Leock Y. Ngo
Objective: Study 311 (NCT02849626) was a global, multicenter, open‐label, single‐arm study that assessed safety, tolerability, pharmacokinetics, and pharmacokinetics/pharmacodynamics of once‐daily adjunctive perampanel oral suspension in pediatric patients (aged 4 to <12 years) with focal seizures (FS) (with/without focal to bilateral tonic‐clonic seizures [FBTCS]) or generalized tonic‐clonic seizures (GTCS).Methods: In the 311 Core Study, a 4‐week Pre‐treatment Period (Screening/Baseline) preceded a 23‐week Treatment Period (11‐week Titration; 12‐week Maintenance) and 4‐week Follow‐up. Endpoints included safety/tolerability (primary endpoint), median percent change in seizure frequency per 28 days from Baseline (Treatment Period), and 50% responder and seizure‐freedom rates (Maintenance Period). Patients were stratified by age (4 to <7; 7 to <12 years) and concomitant enzyme‐inducing anti‐seizure drug (EIASD) use.Results: One hundred eighty patients were enrolled (FS, n = 149; FBTCS, n = 54; GTCS, n = 31). The Core Study was completed by 146 patients (81%); the most common primary reason for discontinuation was adverse event (AE) (n = 14 [8%]). Mean (standard deviation) daily perampanel dose was 7.0 (2.6) mg/day and median (interquartile range) duration of exposure was 22.9 (2.0) weeks. The overall incidence of treatment‐emergent AEs (TEAEs; 89%) was similar between patients with FS (with/without FBTCS) and GTCS. The most common TEAEs were somnolence (26%) and nasopharyngitis (19%). There were no clinically important changes observed for cognitive function, laboratory, or electrocardiogram (ECG) parameters or vital signs. Median percent reductions in seizure frequency per 28 days from Baseline were as follows: 40% (FS), 59% (FBTCS), and 69% (GTCS). Corresponding 50% responder and seizure‐freedom rates were as follows: FS, 47% and 12%; FBTCS, 65% and 19%; and GTCS, 64% and 55%, respectively. Improvements in response/seizure frequency from Baseline were seen regardless of age or concomitant EIASD use.Significance: Results from the 311 Core Study suggest that daily oral doses of adjunctive perampanel are generally safe, well tolerated, and efficacious in children age 4 to <12 years with FS (with/without FBTCS) or GTCS.

27 April 2005 in Epilepsia
Verified
Journal Article
Closed access
PDF file
ZSZsuzsanna Siegler
Zsuzsanna Siegler
PBPeter Barsi
Peter Barsi
MNMagdolna Neuwirth
Magdolna Neuwirth
JJJudit Jerney
Judit Jerney
MKMaria Kassay
Maria Kassay
AFAndras Fogarasi
Andras Fogarasi

23 May 2007 in Epilepsia
Verified
Journal Article
Closed access
PDF file
AFAndrás Fogarasi
András Fogarasi
ITIngrid Tuxhorn
Ingrid Tuxhorn
JJJózsef Janszky
József Janszky
IJImre Janszky
Imre Janszky
GRGyörgy Rásonyi
György Rásonyi
PHPéter Halász
Péter Halász

2 September 2021 in Disability and Rehabilitation
Verified
Journal Article
Open access
AFAndras Fogarasi
Andras Fogarasi
EFElisa Fazzi
Elisa Fazzi
ASAna R. P. Smorenburg
Ana R. P. Smorenburg
MMMaria Mazurkiewicz-Beldzinska
Maria Mazurkiewicz-Beldzinska
ADArgirios Dinopoulos
Argirios Dinopoulos
SYSanem Keskin Yilmaz
Sanem Keskin Yilmaz
To obtain information on characteristics, management, current objective nutritional status and perception of nutritional status of children with cerebral palsy (CP) from healthcare professionals (H...

1 June 2011 in Epilepsy Research
Verified
Journal Article
Closed access
ÁVÁbel Velkey
Ábel Velkey
ZSZsuzsanna Siegler
Zsuzsanna Siegler
JJJózsef Janszky
József Janszky
BDBorbála Duray
Borbála Duray
AFAndrás Fogarasi
András Fogarasi